Novartis AG received FDA approval for Scemblix®, a new treatment for newly diagnosed chronic myeloid leukemia (CML) patients, showing superior efficacy—68% achieving major molecular response compared to 49% with standard treatments. This approval expands access to a potential new standard of care for four times as many patients, addressing significant treatment challenges.